Molecular Basis of Selective Cytokine Signaling Inhibition by Antibodies Targeting a Shared Receptor.

Autor:	Fields JK; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.; Department of Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, MD, United States.; Program in Molecular Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, United States., Kihn K; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, United States., Birkedal GS; Cantargia AB, Lund, Sweden., Klontz EH; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.; Department of Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, MD, United States.; Program in Molecular Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, United States., Sjöström K; Innovagen AB, Lund, Sweden., Günther S; Center for Free-Electron Laser Science, Deutsches Elektronen-Synchrotron (DESY), Hamburg, Germany., Beadenkopf R; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States., Forsberg G; Cantargia AB, Lund, Sweden., Liberg D; Cantargia AB, Lund, Sweden., Snyder GA; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.; Department of Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, MD, United States., Deredge D; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, United States., Sundberg EJ; Department of Biochemistry, Emory School of Medicine, Atlanta, GA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2021 Dec 24; Vol. 12, pp. 779100. Date of Electronic Publication: 2021 Dec 24 (Print Publication: 2021).
DOI:	10.3389/fimmu.2021.779100
Abstrakt:	Interleukin-1 (IL-1) family cytokines are potent mediators of inflammation, acting to coordinate local and systemic immune responses to a wide range of stimuli. Aberrant signaling by IL-1 family cytokine members, however, is linked to myriad inflammatory syndromes, autoimmune conditions and cancers. As such, blocking the inflammatory signals inherent to IL-1 family signaling is an established and expanding therapeutic strategy. While several FDA-approved IL-1 inhibitors exist, including an Fc fusion protein, a neutralizing antibody, and an antagonist cytokine, none specifically targets the co-receptor IL-1 receptor accessory protein (IL-1RAcP). Most IL-1 family cytokines form productive signaling complexes by binding first to their cognate receptors - IL-1RI for IL-1α and IL-1β; ST2 for IL-33; and IL-36R for IL-36α, IL-36β and IL-36γ - after which they recruit the shared secondary receptor IL-1RAcP to form a ternary cytokine/receptor/co-receptor complex. Recently, IL-1RAcP was identified as a biomarker for both AML and CML. IL-1RAcP has also been implicated in tumor progression in solid tumors and an anti-IL1RAP antibody (nadunolimab, CAN04) is in phase II clinical studies in pancreatic cancer and non-small cell lung cancer (NCT03267316). As IL-1RAcP is common to all of the abovementioned IL-1 family cytokines, targeting this co-receptor raises the possibility of selective signaling inhibition for different IL-1 family cytokines. Indeed, previous studies of IL-1β and IL-33 signaling complexes have revealed that these cytokines employ distinct mechanisms of IL-1RAcP recruitment even though their overall cytokine/receptor/co-receptor complexes are structurally similar. Here, using functional, biophysical, and structural analyses, we show that antibodies specific for IL-1RAcP can differentially block signaling by IL-1 family cytokines depending on the distinct IL-1RAcP epitopes that they engage. Our results indicate that targeting a shared cytokine receptor is a viable therapeutic strategy for selective cytokine signaling inhibition. Competing Interests: DL, GF, and GB are employees of Cantargia AB (Medicon Village, Lund, Sweden). KS is an employee of Innovagen AB (Lund, Sweden). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received partial funding from Cantargia AB. The funder had the following involvement in the study: data collection and analysis, decision to publish. Cantargia AB is the owner of the intellectual property rights for CAN03 and CAN04 for use in the treatment and diagnosis of neoplastic disorders. (Copyright © 2021 Fields, Kihn, Birkedal, Klontz, Sjöström, Günther, Beadenkopf, Forsberg, Liberg, Snyder, Deredge and Sundberg.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu